CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry

Neuropathology

Volumn 33, Issue 4, 2013, Pages 405-412

  Purkait, Suvendu ^a   Jha, Prerana ^a   Sharma, Mehar Chand ^a   Suri, Vaishali ^a   Sharma, Manish ^a   Kale, Shashank Sharad ^a   Sarkar, Chitra ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Adult GBM; CDKN2A; Glioma; P16; Pediatric GBM

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P16; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADULT GBM; CDKN2A; GLIOMA; P16; PEDIATRIC GBM;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE DELETION; GENES, P16; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84881312974     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12014     Document Type: Article

References (38)

1. CBTRUS. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2010; [Cited Feb 2010.] Available from URL: http://www.cbtrus.org
2. Korshunov A, Sycheva R, Gorelyshev S, Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005; 18: 1258-1263.
3. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
4. Stupp R, Mason WP, van den Bent MJ etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
5. Stupp R, Hegi ME, Mason WP etal. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
6. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378: 115-177.
7. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995; 83: 993-1000.
8. Ivanchuk SM, Mondal S, Dirks PB, Rutka JT. The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. J Neurooncol 2001; 51: 219-229.
9. Berger JH, Bardeesy N. Modeling INK4/ARF tumor suppression in the mouse. Curr Mol Med 2007; 7: 63-75.
10. Moulton T, Samara G, Chung W-Y etal. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Pathol 1995; 146: 613-619.
11. Miettinen H, Kononen J, Sallinen P etal. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas. J Neurooncol 1999; 41: 205-211.
12. Labuhn M, Jones G, Speel EJ etal. Quantitative real-time PCR does not show selective targeting of p14(ARF) but concomitant inactivation of both p16(INK4A) and p14(ARF) in 105 human primary gliomas. Oncogene 2001; 20: 1103-1109.
13. Batchelor TT, Betensky RA, Esposito JM etal. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004; 10: 228-233.
14. Brat DJ, Seiferheld WF, Perry A etal. Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. Neuro Oncol 2004; 6: 96-103.
15. Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer 2005; 104: 825-832.
16. Fukushima T, Favereaux A, Huang H etal. Genetic alterations in primary glioblastomas in Japan. J Neuropathol Exp Neurol 2006; 65: 12-18.
17. Ohgaki H, Dessen P, Jourde B etal. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
18. Martinez R, Rohde V, Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2010; 96: 321-329.
19. Kamiryo T, Tada K, Shiraishi S etal. Analysis of homozygous deletion of the p16 gene and correlation with survival in patients with glioblastoma multiforme. J Neurosurg 2002; 96: 815-822.
20. Raffel C, Frederick L, O'Fallon JR etal. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999; 5: 4085-4090.
21. Rao LS, Miller DC, Newcomb EW. Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas. Diagn Mol Pathol 1997; 6: 115-122.
22. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998; 57: 122-130.
23. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
24. Ohgaki H, Kleihues P. Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 2009; 100: 2235-2241.
25. Jha P, Suri V, Singh G etal. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 2011; 20: 225-232.
26. Perry A, Nobori T, Ru N etal. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol 1997; 56: 999-1008.
27. Petitjean A, Mathe E, Kato S etal. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53database. Hum Mutat 2007; 28: 622-629.
28. Russo AA, Tong L, Lee JO, Jeffrey PD, Pavletich NP. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumor suppressor p16INK4a. Nature 1998; 395: 237-243.
29. Arap W, Nishikawa R, Furnari FB, Cavenee WK, Su Huang HJ. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 1995; 55: 1351-1354.
30. Fueyo J, Gomez-Manzano C, Yung AWK etal. Adenovirus- mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 1996; 12: 103-110.
31. Shih HA, Betensky RA, Dorfman MV, Louis DN, Loeffler JS, Batchelor TT. Genetic analyses for predictors of radiation response in glioblastoma. Int J Radiat Oncol Biol Phys 2005; 63: 704-710.
32. Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol 2008; 87: 111-114.
33. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro-oncol 2004; 6: 227-235.
34. Biernat W, Tohma Y, Yonekawa Y, Kleihues P, Ohgaki H. Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas. Acta Neuropathol 1997; 94: 303-309.
35. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol 2008; 21: 742-747.
36. Subramaniam MM, Noguera R, Piqueras M, Navarro S, López-Guerrero JA, Llombart-Bosch A. p16INK4A (CDKN2A) gene deletion is a frequent genetic event in synovial sarcomas. Am J Clin Pathol 2006; 126 (6): 866-874.
37. Jha P, Sarkar C, Pathak P etal. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management. Diagn Mol Pathol 2011; 20: 40-47.
38. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol 2002; 12: 67-86.